Asahi Kasei Pharma obtains Chinese approval for Flivas™ (naftopidil) dysuria treatment | 2020 | News | Asahi Kasei

Press Releases

Asahi Kasei Pharma obtains Chinese approval for Flivas™ (naftopidil) dysuria treatment

June 2, 2020
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma obtained a new drug approval in China for Flivas™ (naftopidil), an agent for the treatment of dysuria associated with benign prostatic hyperplasia (BPH), on May 20, 2020.

BPH is a condition in which an enlarged prostate gland causes urinary symptoms such as discomfort, incontinence, incomplete voiding, and nocturia. Naftopidil is an α1-blocker that suppresses the constriction of smooth muscle in the prostate gland and in the urethra, alleviating the discomfort and other symptoms of BPH. It has been sold in Japan since February 1999.

As the population ages in China, the number of patients with dysuria associated with BPH has been increasing. There is thus a growing need for treatments that can improve the quality of life for such patients. Asahi Kasei Pharma hopes that Flivas™ will provide a new option for treating dysuria associated with BPH in China.

Product overview

Product name
福列® in Chinese, Flivas®
Generic name
Naftopidil
Indication
Dysuria associated with benign prostatic hyperplasia
Dosage and administration
For adults, ordinarily administered in 25 mg dosage via oral administration once per day after a meal. Should no sufficient effect be obtained, dosage may be increased to 50 mg and then to 75 mg in one to two week intervals. Dosage may vary depending on the condition, but the maximum dosage is 75 mg per day.
Formulation
Tablets (25 mg and 50 mg)